Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.

Abstract

TERT is of great importance in cancer initiation and progression. Many studies have demonstrated the TERT polymorphisms as risk factors for many cancer types, including lung cancer. However, the impacts of TERT variants on cancer progression and treatment efficacy have remained controversial. This study aimed to investigate the association of TERT polymorphisms with clinical outcome of advanced non-small cell lung cancer (NSCLC) patients receiving first-line platinum-based chemotherapy, including response rate, clinical benefit, progression-free survival (PFS), overall survival (OS), and grade 3 or 4 toxicity. Seven polymorphisms of TERT were assessed, and a total of 1004 inoperable advanced NSCLC patients treated with platinum-based chemotherapy were enrolled. It is exhibited that the variant heterozygote of rs4975605 showed significant association with a low rate of clinical benefit, and displayed a much stronger effect in never-smoking female subset, leading to the clinical benefit rate decreased from 82.9% (C/C genotype) to 56.4% (C/A genotype; adjusted OR, 3.58; P=1.40×10(-4)). It is also observed that the polymorphism rs2736109 showed significant correlation with PFS (log-rank P=0.023). In age > 58 subgroup, patients carrying the heterozygous genotype had a longer median PFS than those carrying the wild-type genotypes (P=0.002). The results from the current study, for the first time to our knowledge, provide suggestive evidence of an effect of TERT polymorphisms on disease progression variability among Chinese patients with platinum-treated advanced NSCLC.

• Authors: Xueying Zhao, Shiming Wang, Junjie Wu, Xiaoying Li, Xun Wang, Zhiqiang Gao, Wenting Wu, Haijian Wang, Jiucun Wang, Ji Qian, Ke Ma, Hui Li, Baohui Han, Chunxue Bai, Qiang Li, Wenbin Liu, Daru Lu
• Journal: PloS one (PLoS One) Vol. 10 Issue 5 Pg. e0129232 ( 2015) ISSN: 1932-6203 [Electronic] United States
• PMID: 26020272 (Publication Type: Journal Article)

Chemical References

• Deoxycytidine
• Vinblastine
• Carboplatin
• TERT protein, human
• Telomerase
• Paclitaxel
• Cisplatin
• Vinorelbine
• Gemcitabine

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Carboplatin (administration & dosage)
• Carcinoma, Non-Small-Cell Lung (diagnosis, drug therapy, genetics, mortality)
• Cisplatin (administration & dosage)
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Disease Progression
• Female
• Gene Expression
• Heterozygote
• Humans
• Lung Neoplasms (diagnosis, drug therapy, genetics, mortality)
• Male
• Middle Aged
• Neoplasm Staging
• Paclitaxel (administration & dosage)
• Polymorphism, Single Nucleotide
• Prognosis
• Survival Analysis
• Telomerase (genetics)
• Treatment Outcome
• Vinblastine (administration & dosage, analogs & derivatives)
• Vinorelbine
• Gemcitabine